Microbix Biosystms (TSE:MBX) has released an update.
Microbix Biosystems Inc. has unveiled a novel Quality Assessment Product (QAP) at the European Meeting on Molecular Diagnostics to enhance the detection and analysis of Herpes Simplex Virus (HSV) infections. The innovative QAP aims to improve both molecular and immunohistochemical tests, contributing to more accurate patient diagnosis and tissue analysis. This advancement comes as part of Microbix’s commitment to supporting high-quality testing in the face of widespread and potentially serious HSV infections.
For further insights into TSE:MBX stock, check out TipRanks’ Stock Analysis page.
